stockrow
Saturday 7 November 2026
Export OSRH’s income statement to Excel — free account
OSR Health, Inc.
OSRH Healthcare Biotechnology
OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024.
- Revenue
- −72.2%
- EPS
- −200.0%
- Free cash flow
- −398.8%
- Total debt
- +28.2%
Quarter to June 2026, against a year earlier
0.15
0.01
+7.14%
Follow OSRH
Alert me
OSR Health, Inc. (OSRH) P/E ratio
OSR Health, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 331× (September 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 331×
Ten-year median
0.0×
Current reading's percentile
79
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OSRH OSR Health, Inc. | n/m |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| AZTR Azitra, Inc. compare | 1.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)